PL3365366T3 - Trójspecyficzne i/lub trójwalentne białka wiążące do zapobiegania lub leczenia zakażenia HIV - Google Patents

Trójspecyficzne i/lub trójwalentne białka wiążące do zapobiegania lub leczenia zakażenia HIV

Info

Publication number
PL3365366T3
PL3365366T3 PL16794472T PL16794472T PL3365366T3 PL 3365366 T3 PL3365366 T3 PL 3365366T3 PL 16794472 T PL16794472 T PL 16794472T PL 16794472 T PL16794472 T PL 16794472T PL 3365366 T3 PL3365366 T3 PL 3365366T3
Authority
PL
Poland
Prior art keywords
trispecific
prevention
treatment
binding proteins
hiv infection
Prior art date
Application number
PL16794472T
Other languages
English (en)
Inventor
Zhi-Yong Yang
Gary J. Nabel
Ling Xu
Ronnie WEI
Huawei Qiu
Jochen Beninga
Jochen Kruip
Ercole Rao
Wulf Dirk LEUSCHNER
Christian Beil
Christian Lange
Mark Connors
John R. Mascola
Richard A. Koup
Jinghe HUANG
Nicole A. Doria-Rose
Tongqing Zhou
Peter D. Kwong
Young Do Kwon
Amarendra PEGU
Mangaiarkarasi ASOKAN
Original Assignee
Sanofi
The Usa, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi, The Usa, As Represented By The Secretary, Department Of Health And Human Services filed Critical Sanofi
Publication of PL3365366T3 publication Critical patent/PL3365366T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL16794472T 2015-10-25 2016-10-24 Trójspecyficzne i/lub trójwalentne białka wiążące do zapobiegania lub leczenia zakażenia HIV PL3365366T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562246113P 2015-10-25 2015-10-25
EP16305211 2016-02-24
US201662322029P 2016-04-13 2016-04-13
US201662331169P 2016-05-03 2016-05-03
PCT/US2016/058540 WO2017074878A1 (en) 2015-10-25 2016-10-24 Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
EP16794472.7A EP3365366B1 (en) 2015-10-25 2016-10-24 Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection

Publications (1)

Publication Number Publication Date
PL3365366T3 true PL3365366T3 (pl) 2022-01-31

Family

ID=55588187

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16794472T PL3365366T3 (pl) 2015-10-25 2016-10-24 Trójspecyficzne i/lub trójwalentne białka wiążące do zapobiegania lub leczenia zakażenia HIV

Country Status (30)

Country Link
US (4) US20190054182A1 (pl)
EP (2) EP3819310A1 (pl)
JP (3) JP7169190B2 (pl)
KR (1) KR102687212B1 (pl)
CN (4) CN109311966B (pl)
AR (1) AR106466A1 (pl)
AU (2) AU2016347058B2 (pl)
BR (1) BR112018008011A2 (pl)
CA (1) CA3002664A1 (pl)
CL (1) CL2018001065A1 (pl)
CO (1) CO2018005337A2 (pl)
CR (1) CR20180288A (pl)
DO (1) DOP2018000102A (pl)
EA (1) EA201891028A1 (pl)
ES (1) ES2894304T3 (pl)
HR (1) HRP20211528T1 (pl)
HU (1) HUE056608T2 (pl)
IL (2) IL301140A (pl)
MA (1) MA42641A1 (pl)
MX (2) MX2018005048A (pl)
MY (1) MY192278A (pl)
PE (1) PE20181167A1 (pl)
PH (1) PH12018500873A1 (pl)
PL (1) PL3365366T3 (pl)
RS (1) RS62437B1 (pl)
SG (1) SG11201803324VA (pl)
SI (1) SI3365366T1 (pl)
TW (3) TWI750139B (pl)
UY (1) UY36965A (pl)
WO (1) WO2017074878A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
EP3110844B1 (en) * 2014-02-28 2020-02-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
KR102687212B1 (ko) * 2015-10-25 2024-07-19 사노피 Hiv 감염의 예방 또는 치료를 위한 3특이성 및/또는 3가 결합 단백질
CA3003878A1 (en) * 2015-11-03 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 gp41 and their use
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
TN2020000058A1 (en) 2016-04-13 2022-01-06 Sanofi Sa Trispecific and/or trivalent binding proteins
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
CA3053774A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
BR112019020235A2 (pt) * 2017-03-27 2020-04-22 The Wistar Institute Of Anatomy And Biology molécula de ácido nucleico, composição, e, métodos para tratar uma doença num indivíduo e para induzir uma resposta imunológica num indivíduo.
TWI728250B (zh) 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
AU2018348093A1 (en) 2017-10-10 2020-05-28 Sanofi Anti-CD38 antibodies and combinations with anti-CD3 and anti-CD28 antibodies
WO2019123262A1 (en) * 2017-12-18 2019-06-27 VIIV Healthcare UK (No.5) Limited Antigen binding polypeptides
CA3085351A1 (en) * 2017-12-21 2019-07-11 Aaron Diamond Aids Research Center Bispecific hiv-1-neutralizing antibodies
EP3737949A1 (en) 2018-01-12 2020-11-18 Genzyme Corporation Methods for the quantitation of polypeptides
WO2019226829A1 (en) 2018-05-22 2019-11-28 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
CA3115679A1 (en) * 2018-10-09 2020-04-16 Sanofi Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
US12459989B2 (en) * 2018-11-21 2025-11-04 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (HIV)
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
WO2020210392A1 (en) * 2019-04-09 2020-10-15 Sanofi Trispecific binding proteins, methods, and uses thereof
CN114829393A (zh) 2019-10-25 2022-07-29 赛诺菲 用于分析多特异性结合蛋白中的链错配的方法
US20230203466A1 (en) * 2020-04-03 2023-06-29 Medgenome Inc. Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
AU2021333577B2 (en) 2020-08-25 2025-09-11 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting HIV and methods of use
MX2024003804A (es) * 2021-09-29 2024-06-11 Modex Therapeutics Inc Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos en el vih.
CN118591388A (zh) * 2021-09-29 2024-09-03 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
KR20240099224A9 (ko) * 2021-09-29 2025-12-10 모덱스 테라퓨틱스, 인크. 항원 결합 폴리펩티드, 항원 결합 폴리펩티드 복합체 및 이의 사용 방법
WO2025109206A1 (en) 2023-11-22 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025108551A1 (en) 2023-11-23 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
US20250376537A1 (en) 2024-05-17 2025-12-11 Sanofi Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
CN101684158A (zh) 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
CA2774636C (en) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
CN103282385A (zh) 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI838039B (zh) * 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CN116948019A (zh) * 2011-05-17 2023-10-27 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
RU2624046C2 (ru) 2011-11-07 2017-06-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз Gp41-нейтрализующие антитела и их применение
ES2749349T3 (es) * 2011-11-07 2020-03-19 Medimmune Llc Proteínas de unión multiespecíficas y multivalentes y usos de las mismas
AU2012347453B2 (en) 2011-12-08 2017-11-23 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
WO2013163427A1 (en) * 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
HK1215950A1 (zh) * 2012-09-25 2016-09-30 艾科诺斯科技股份有限公司 异源二聚免疫球蛋白的纯化
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
KR20230156146A (ko) 2012-12-13 2023-11-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｄｎａ 항체 작제물 및 그 이용 방법
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US20140242077A1 (en) * 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2014131712A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
MX2015013170A (es) 2013-03-15 2016-07-26 Abbvie Inc Proteinas de union especificas duales dirigidas contra tnf alpha.
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CA2954168C (en) 2013-08-02 2023-09-19 The Regents Of The University Of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
WO2015063339A1 (en) 2013-11-04 2015-05-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
ES2808914T3 (es) 2014-09-04 2021-03-02 Stemcell Tech Inc Complejos de anticuerpo solubles para la activación y expansión de linfocitos T o células NK
EP3812398A3 (en) 2015-01-23 2021-07-21 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2016187580A1 (en) 2015-05-20 2016-11-24 Quantum-Si Incorporated Method of determining the sequence of a nuclear acid using time resolved luminescence
US10654943B2 (en) 2015-06-02 2020-05-19 The Rockefeller University Tri-specific antibodies for HIV therapy
US10738099B2 (en) 2015-09-22 2020-08-11 The Trustees Of The University Of Pennsylvania Method of redirecting T cells to treat HIV infection
KR102687212B1 (ko) 2015-10-25 2024-07-19 사노피 Hiv 감염의 예방 또는 치료를 위한 3특이성 및/또는 3가 결합 단백질
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
PL3390441T3 (pl) 2015-12-15 2022-01-10 Gilead Sciences, Inc. Przeciwciała neutralizujące ludzki wirus niedoboru odporności
TN2020000058A1 (en) 2016-04-13 2022-01-06 Sanofi Sa Trispecific and/or trivalent binding proteins
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
WO2018120842A1 (zh) 2016-12-30 2018-07-05 上海欣百诺生物科技有限公司 一种双功能分子及其应用
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
CA3053774A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
BR112019020235A2 (pt) 2017-03-27 2020-04-22 The Wistar Institute Of Anatomy And Biology molécula de ácido nucleico, composição, e, métodos para tratar uma doença num indivíduo e para induzir uma resposta imunológica num indivíduo.
AU2018348093A1 (en) 2017-10-10 2020-05-28 Sanofi Anti-CD38 antibodies and combinations with anti-CD3 and anti-CD28 antibodies
CA3115679A1 (en) 2018-10-09 2020-04-16 Sanofi Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
CA3002664A1 (en) 2017-05-04
KR102687212B1 (ko) 2024-07-19
CN116789841A (zh) 2023-09-22
PE20181167A1 (es) 2018-07-19
MA42641A1 (fr) 2019-03-29
EA201891028A1 (ru) 2019-02-28
JP7328267B2 (ja) 2023-08-16
SI3365366T1 (sl) 2022-02-28
HUE056608T2 (hu) 2022-02-28
NZ781602A (en) 2025-07-25
JP7169190B2 (ja) 2022-11-10
CO2018005337A2 (es) 2018-07-10
MY192278A (en) 2022-08-16
PH12018500873A1 (en) 2018-11-12
IL258822A (en) 2018-06-28
TW202219064A (zh) 2022-05-16
WO2017074878A1 (en) 2017-05-04
EP3365366A1 (en) 2018-08-29
US11129905B2 (en) 2021-09-28
IL258822B2 (en) 2023-08-01
NZ742825A (en) 2024-04-26
JP2018537966A (ja) 2018-12-27
EP3819310A1 (en) 2021-05-12
DOP2018000102A (es) 2018-11-30
CN109311966A (zh) 2019-02-05
JP2023085476A (ja) 2023-06-20
JP2021072847A (ja) 2021-05-13
KR20180063336A (ko) 2018-06-11
US20250312475A1 (en) 2025-10-09
SG11201803324VA (en) 2018-05-30
MX2022014631A (es) 2023-01-11
EP3365366B1 (en) 2021-07-14
IL258822B1 (en) 2023-04-01
CN109311966B (zh) 2023-03-10
US20190054182A1 (en) 2019-02-21
IL301140A (en) 2023-05-01
AU2024200395A1 (en) 2024-04-11
WO2017074878A8 (en) 2018-05-24
AU2016347058B2 (en) 2023-11-09
CR20180288A (es) 2018-09-11
TW201730210A (zh) 2017-09-01
BR112018008011A2 (en) 2018-10-30
US20200054765A1 (en) 2020-02-20
US20220226495A1 (en) 2022-07-21
AU2016347058A1 (en) 2018-06-14
CN116675776A (zh) 2023-09-01
US11779651B2 (en) 2023-10-10
RS62437B1 (sr) 2021-11-30
UY36965A (es) 2017-05-31
HK1253385A1 (zh) 2019-06-14
CL2018001065A1 (es) 2018-11-23
HRP20211528T1 (hr) 2021-12-24
JP7724814B2 (ja) 2025-08-18
AR106466A1 (es) 2018-01-17
TWI750139B (zh) 2021-12-21
TW202442675A (zh) 2024-11-01
MX2018005048A (es) 2018-09-06
CN117069855A (zh) 2023-11-17
ES2894304T3 (es) 2022-02-14

Similar Documents

Publication Publication Date Title
IL258822A (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
IL262241A (en) Trispecific and/or trivalent binding proteins
IL269536A (en) Compounds and compositions for treating hematological disorders
IL253243A0 (en) Combined preparations for the treatment of cancer or infection
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
IL258259B (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
IL258459A (en) Therapeutic compositions for treatment of human immunodeficiency virus
ZA201705634B (en) Quinoline derivatives for use in the treatment or prevention of viral infection
IL263368A (en) Prevention and treatment of viral infections
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
IL253983A0 (en) Compositions and methods of treating fanconi anemia
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
ZA202006103B (en) Trispecific and/or trivalent binding proteins
IL284124A (en) Quinoline derivatives for use in the treatment or prevention of cancer
DK3373922T3 (da) Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri
SG11201809811VA (en) Compositions and methods for treatment of inflammation or infection of the eye
PL3459542T3 (pl) Zastosowanie związku karbaminianu do zapobiegania lub leczenia neuralgii nerwu trójdzielnego
DK3383381T3 (da) Forbindelse til anvendelse til forebyggelse og behandling af neurodegenerative sygdomme
GB201615035D0 (en) Treatment and prevention of viral infection
EP3170533C0 (en) Bandage and kit for the treatment of wounds
PL3193859T3 (pl) Preparaty do leczenia i zapobiegania czerwienieniu po alkoholu i reakcjom nadwrażliwości wywołanym alkoholem
DK3191112T3 (da) Dipeptidylketoamidforbindelser og anvendelse deraf til behandling og/eller forebyggelse af fedtophobning
IL258116A (en) Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
SG10202003467RA (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection